Celon Pharma SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLCLNPH00015
PLN
19.72
-0.12 (-0.6%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationQuarterly Results
Results Snapshot
YoYQoQ
Figures in Million
Consolidate Quarterly Results
Mar'26
Dec'25
Sep'25
Jun'25
Mar'25
Sep'24
Jun'24
Net Sales
57.51
53.99
54.63
51.86
49.32
119.70
53.57
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
57.51
53.99
54.63
51.86
49.32
119.70
53.57
Raw Material Cost
63.91
57.77
60.86
66.50
64.11
59.92
63.71
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
23.07
19.06
21.08
21.04
22.48
17.73
21.73
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
0.50
0.34
0.34
0.30
0.49
0.49
0.68
Selling and Distribution Expenses
3.85
3.59
5.23
4.66
3.80
3.78
8.47
Other Expenses
-2.36
-1.94
-2.14
-2.13
-2.30
-1.82
-2.24
Total Expenditure (Excl Depreciation)
67.76
61.36
66.09
71.16
67.91
63.70
72.19
Operating Profit (PBDIT) excl Other Income
-10.2
-7.4
-11.5
-19.3
-18.6
56
-18.6
Other Income
173.10
8.93
21.19
5.03
0.58
0.59
14.74
Operating Profit (PBDIT)
173.98
12.33
20.74
-3.05
-4.74
69.72
8.56
Interest
0.50
0.34
0.34
0.30
0.49
0.49
0.68
Exceptional Items
0.00
0.96
-1.35
-1.84
0.14
1.79
-5.80
Gross Profit (PBDT)
-6.40
-3.79
-6.23
-14.64
-14.80
59.78
-10.14
Depreciation
11.13
10.78
11.01
11.23
13.27
13.13
12.43
Profit Before Tax
162.35
2.17
8.03
-16.42
-18.36
57.89
-10.35
Tax
-2.26
18.33
-6.43
5.92
2.58
0.71
-2.33
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
162.60
-24.90
3.66
-32.76
-25.09
57.17
-8.03
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
162.60
-24.90
3.66
-32.76
-25.09
57.17
-8.03
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
162.60
-24.90
3.66
-32.76
-25.09
57.17
-8.03
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.1
0.1
0.1
0.1
0.1
0.1
0.1
Reserves
528.78
363.25
389.19
385.11
419.53
516.25
459.37
Earnings per share (EPS)
3.06
-0.46
0.07
-0.61
-0.47
1.06
-0.16
Diluted Earnings per share
3.06
-0.46
0.07
-0.61
-0.47
1.06
-0.16
Operating Profit Margin (Excl OI)
-17.82%
-13.66%
-20.98%
-37.23%
-37.7%
46.78%
-34.75%
Gross Profit Margin
301.68%
23.98%
34.85%
-10.01%
-10.32%
59.33%
3.89%
PAT Margin
282.75%
-46.12%
6.7%
-63.18%
-50.86%
47.76%
-14.98%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Analysis Highlights - YoY
stock-summary

Net Sales

YoY Growth in quarter ended Mar 2026 is 16.63% vs 35.81% in Mar 2025

stock-summary

Consolidate Net Profit

YoY Growth in quarter ended Mar 2026 is 747.81% vs -59.87% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in quarter ended Mar 2026 is 116.98% vs 41.76% in Mar 2025

stock-summary

Interest

YoY Growth in quarter ended Mar 2026 is 0.00% vs -97.19% in Mar 2025

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025

Compare Quarterly Results Of Celon Pharma SA With
Markets Mojo
Figures in Million
Consolidate Quarterly Results
Markets Mojo
Markets Mojo
Change(PLN)
Change(%)
Net Sales
57.51
16.95
40.56
239.29%
Other Operating Income
0.00
0.00
0.00
Total Operating income
57.51
16.95
40.56
239.29%
Raw Material Cost
63.91
33.01
30.90
93.61%
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
23.07
11.84
11.23
94.85%
Power Cost
0
0
0.00
Manufacturing Expenses
0.50
2.24
-1.74
-77.68%
Selling and Distribution Expenses
3.85
0.76
3.09
406.58%
Other Expenses
-2.36
-1.41
-0.95
-67.38%
Total Expenditure (Excl Depreciation)
67.76
33.77
33.99
100.65%
Operating Profit (PBDIT) excl Other Income
-10.25
-16.82
6.57
39.06%
Other Income
173.10
4.58
168.52
3,679.48%
Operating Profit (PBDIT)
173.98
-10.43
184.41
1,768.07%
Interest
0.50
2.24
-1.74
-77.68%
Exceptional Items
0.00
2.35
-2.35
-100.00%
Gross Profit (PBDT)
-6.40
-16.06
9.66
60.15%
Depreciation
11.13
2.15
8.98
417.67%
Profit Before Tax
162.35
-12.47
174.82
1,401.92%
Tax
-2.26
0.18
-2.44
-1,355.56%
Provisions and contingencies
0
0
0.00
Profit After Tax
162.60
-12.65
175.25
1,385.38%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
162.60
-12.65
175.25
1,385.38%
Share in Profit of Associates
0
0
0.00
Minority Interest
0.00
0.00
0.00
Other related items
0.00
0.00
0.00
Consolidated Net Profit
162.60
-12.65
175.25
1,385.38%
Equity Capital
0
0
0.00
Face Value
0.10
0.40
0.00
Reserves
528.78
41.33
487.45
1,179.41%
Earnings per share (EPS)
3.06
-0.55
3.61
656.36%
Diluted Earnings per share
3.06
-0.55
3.61
656.36%
Operating Profit Margin (Excl OI)
-17.82%
-101.20%
0.00
83.38%
Gross Profit Margin
301.68%
-60.88%
0.00
362.56%
PAT Margin
282.75%
-74.61%
0.00
357.36%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Quarterly - Net Sales
Net Sales 5.75 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 6.48% vs -1.10% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 16.63% vs 35.81% in Mar 2025

Quarterly - Consolidate Net Profit
Consolidate Net Profit 16.26 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 753.01% vs -772.97% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 747.81% vs -59.87% in Mar 2025

Quarterly - Operating Profit (PBDIT)
Operating Profit (PBDIT) 0.09 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is -73.53% vs 780.00% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 116.98% vs 41.76% in Mar 2025

Quarterly - Interest
Interest 0.05 Million
in Mar 2026

Figures in Million
stock-summary

QoQ Growth in quarter ended Mar 2026 is 66.67% vs 0.00% in Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 is 0.00% vs -97.19% in Mar 2025

Quarterly - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -17.82%
in Mar 2026

Figures in %
stock-summary

QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025

stock-summary

YoY Growth in quarter ended Mar 2026 has improved from Mar 2025